Press release

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Outlook Therapeutics, Inc. (BCS)

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Outlook Therapeutics, Inc. (NASDAQ:OTLK) securities between December 29, 2022 and August 29, 2023. Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The Company's lead product candidate is ONS-5010, an ophthalmic formulation of the antibody bevacizumab for the treatment of wet age-related macular degeneration ("wet AMD") and other retina diseases.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: Outlook Therapeutics, Inc. (OTLK) Misled Investors About the Viability and Efficacy of its Lead Product Candidate

According to the complaint, during the class period, defendants failed to disclose that: (i) there was a lack of substantial evidence supporting ONS-5010 as a treatment for wet AMD; (ii) Outlook and/or its manufacturing partner had deficient chemistry ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner

More to read